使用Player FM应用程序离线!
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
Manage episode 346581938 series 3256997
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
- Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
- Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
- Approval of ibrutinib/venetoclax combination therapy for patients with CLL
- Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
- How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor
Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm
168集单集
Manage episode 346581938 series 3256997
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
- Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
- Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
- Approval of ibrutinib/venetoclax combination therapy for patients with CLL
- Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
- How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor
Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm
168集单集
所有剧集
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。